About Jimena Vicencio
Articles by Jimena Vicencio, MD
How Patients’ Income Impacts Hospital Readmissions in AMLMar 27, 2025
HealthTree Community Event: Your Treatment Roadmap After AML DiagnosisMar 19, 2025
How Practice Settings Shape Patient Care in Low-Risk MDSMar 05, 2025
New CAR-T Therapy Targets CD22 to Treat Follicular and Mantle Cell LymphomaFeb 28, 2025
Research News on Frailty in Blood Cancer PatientsFeb 25, 2025
The Role of Frailty in MDS TreatmentFeb 25, 2025
Why Anemia is Common in MDSFeb 24, 2025
Findings from an International Phase 3 Trial: Uproleselan for Relapsed/Refractory AMLFeb 16, 2025
Love Heals: How Partner Support Can Improve Outcomes in ASCTFeb 13, 2025
Glofitamab for Follicular LymphomaFeb 11, 2025
New Treatments for Improving Low Blood Cell Counts in Myelofibrosis PatientsFeb 11, 2025
Study Highlights The Need for Risk Models in AML for Black PatientsFeb 06, 2025
The Role of Minimal Residual Disease (MRD) in Acute Lymphoblastic LeukemiaFeb 03, 2025
Ruxolitinib and Anemia in Myelofibrosis: Real-World Survival Outcomes in the United StatesFeb 03, 2025
FDA Approval of Treosulfan for AML and MDSFeb 02, 2025
Understanding Rare CNS Involvement in Large B-Cell Lymphoma: Largest Study YetJan 23, 2025
How Transfusions Can Impact Quality of Life for Myelofibrosis PatientsJan 22, 2025
Stem Cell Transplant Outcomes for Follicular Lymphoma, A Key Benchmark for New TherapiesJan 22, 2025
The Latest in Pediatric AML Research and InnovationsJan 16, 2025- How Blood Clotting and Bleeding Complications Impact MDS Patients' SurvivalJan 05, 2025
Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024Dec 27, 2024
CAR T-Cell Therapy: Long-Term Side Effects and Patient Outcomes from ASH 2024Dec 23, 2024
Holiday Infection Prevention Guide for Blood Cancer PatientsDec 22, 2024
Epcoritamab as Single Therapy for Relapsed/Refractory CLL/SLLDec 19, 2024
